leisure time -WSS

leisure time

author：knowledge 2025-09-27 12:35:33 - browse：2934

Photo illustration with orange background of Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) -- biotech coverage from STAT — Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) Illustration: Christine Kao/STAT; Courtesy: Steve Shoffner & Michael Haber

After three years being incubated by California VC Westlake Village BioPartners, a new biotech launched Wednesday with $135 million and plans to compete with Vertex Pharmaceuticals.

The startup is called Latigo Biotherapeutics, and it’s launching having already started a Phase 1 trial for a non-opioid pain medicine, LTG-001. The oral therapy is designed to silence pain-signaling neurons by blocking a sodium channel called NaV 1.8.

Westlake had set out years ago to scout out new options for pain medicines, and found a research desert, according to founding managing director Sean Harper. But NaV 1.8 has emerged as a promising option because of its potential to be non-addictive and to lessen pain without affecting a person’s central nervous system, digestion, or heart rate, as opioids can. There were still few high-quality molecules in development that could be licensed from an academic lab or another drug company, so Westlake decided to develop its own.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Congressmen charge Covid hearing ‘could have been an email’

hotspot

WSS

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

The real point of Kenneth Smith’s execution by nitrogen gas

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Quicker fix for pulse oximeters urged during FDA public meeting

Covid misinformation case heads to Supreme Court

Elizabeth Holmes banned from government health programs

Wikipedia

leisure time

focus

Bright Health sells Medicare Advantage business to Molina

eGenesis tests gene

In age of alternative facts, a scholarly course on calling out crap

Woodcock on FDA’s accelerated approval and her next chapter

Psychedelics group wrestles with new pharma identity

FDA clears AI tool for detecting skin cancer

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

FDA clears AI tool for detecting skin cancer

As demand for Covid shots wanes, Moderna seeks its next success

Some dementia cases could be undiagnosed liver disease

entertainment

New brain studies show LSD's effects on the brain in full color

Medicare Advantage today, explained in one chart

The real point of Kenneth Smith’s execution by nitrogen gas

Covid misinformation case heads to Supreme Court

My yearlong odyssey to get my son’s ADHD medication covered

New brain studies show LSD's effects on the brain in full color

hotspot

hotspot

explore

knowledge